Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
Summary not available.
NRx Pharmaceuticals (Nasdaq: NRXP) reported that subsidiary HOPE Therapeutics has treated its first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, Florida.
The AI-guided, sub-millimetric navigation is integrated into outpatient TMS workflows and supports NRx's planned SPARC-TMS trial of NRX-101 with robotic-enabled TMS for depression and suicidality.
Summary not available.
ZETA SURGICAL and HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), reported the first patient treated with the FDA-cleared Zeta TMS Navigation System at a Sarasota clinic on June 23, 2026.
Systems are installed in Sarasota and West Palm Beach, using AI-based RealTrack™ image guidance for sub-millimetric TMS targeting in treatment-resistant depression and other neuropsychiatric conditions.
NRx Pharmaceuticals (Nasdaq: NRXP) received FDA authorization for an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, to augment accelerated Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression.
The company has also initiated the pivotal SPARC-TMS trial in civilian and military settings and will initially provide NRX-101 under expanded access at no cost other than shipping and FDA-required data collection.
NRx Pharmaceuticals (Nasdaq: NRXP)/b) highlighted a peer-reviewed poster presented at the 2026 American Society of Clinical Psychopharmacology conference. The Osmind/Yale study used Real World Evidence from 8,224 IV ketamine and 1,830 intranasal esketamine patients with treatment-resistant depression.IV ketamine showed higher remission (34% vs 26%) and response (63% vs 58%) rates, with odds ratios of 1.51 for remission and 1.22 for response. Authors stressed key limitations, including non-randomized treatment assignment and data drawn only from clinics using Osmind’s electronic medical record system.
NRx Pharmaceuticals (Nasdaq: NRXP) closed a public offering of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds, including the underwriters’ option. The company plans to use net proceeds for working capital and general corporate purposes to support growth.
NRx Pharmaceuticals (Nasdaq: NRXP) priced an underwritten public offering of 5,714,286 common shares at $3.50 per share, targeting approximately $20.0 million in gross proceeds, or $23.0 million if the underwriters’ 30-day option for 857,142 additional shares is fully exercised.
The offering is expected to close on June 4, 2026, subject to customary conditions. Net proceeds are intended for working capital and general corporate purposes to support growth. The deal uses an effective Form S-3 shelf registration statement, with BTIG and Lucid Capital Markets as bookrunning managers.
NRx Pharmaceuticals (Nasdaq: NRXP) plans an underwritten public offering of common stock under its effective Form S-3 shelf registration. The company expects to grant underwriters a 30-day option for up to an additional 15% of shares and intends to use net proceeds for working capital and general corporate purposes.
NRx Pharmaceuticals (Nasdaq: NRXP) announced that strategic partner Emobot Health presented late-breaking pooled clinical validation data for the EMOCARE Depression Thermometer at ASCP 2026.
Across three observational studies, EMOCARE showed within-person concordance with clinician-rated MADRS of r = 0.895 (p = 0.016) and sensitivity to symptom change versus PHQ-9 of ρ = 0.834 (p < 0.001). The smartphone-based, multimodal, passive monitoring tool uses voice, facial expression, motion, and screen behavior to generate continuous depression scores and is being deployed across the Hope Therapeutics interventional psychiatry clinic network as a self-monitoring and safety-net tool.